diaccurate.png

Management team

dominique_bridon.png

Dominique Bridon, M.D.

CEO

jacques_theze.png

Prof. Jacques Thèze

CSO

In summary

DIACCURATE develops a monoclonal antibody (Plazumab) aiming to restore normal CD4+ T-cell activity in certain cancers and severe infectious diseases.

They talk about it

dominique_bridon.png

We think we could have proof of concept in HIV population. Then we will investigate which tumor we can apply it to.

It does not respond to current immunotherapy and it’s a terrible disease. We have preliminary data that say we should continue working down that line

News

homeslider.jpg

Next start-up

Geocorail